Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.

The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration constraints of oral semaglutide, orforglipron offers a major convenience advantage: it is a small molecule with ~79% oral bioavailability that requires no food or water restrictions. Mechanistically, it acts by stimulating cyclic adenosine monophosphate without inducing β-arrestin recruitment, thus potentially limiting receptor desensitization and tachyphylaxis. Phase 3 trials demonstrated potent, dose-dependent efficacy. In the ACHIEVE-3 head-to-head trial (T2DM), orforglipron 36 mg proved superior to oral semaglutide 14 mg, delivering significantly greater reductions in hemoglobin A1c (-2.2% vs -1.4%) and body weight (-9.2% vs -5.3%). In the ATTAIN-2 trial (obesity and T2DM), the same dose achieved 10.5% mean weight loss. The safety profile is consistent with the GLP-1 RA class, dominated by manageable gastrointestinal events mitigated by slow dose escalation. A nondose-dependent heart rate increase and a small signal for mild pancreatitis were observed. A class-specific concern exists regarding increased ventricular arrhythmia risk in patients with heart failure with reduced ejection fraction treated with conventional GLP-1 RAs.